2 Tuberculosis (TB) is the leading cause of death from a single infectious agent in the world today 1 . The only currently-licensed vaccine against TB, M.bovis Bacille Calmette Guerin (BCG), protects against TB meningitis in infants and children, but has variable efficacy in protecting against adult pulmonary TB. 2 Development of a novel TB vaccine is therefore of paramount importance for the status of global health. Although a clear correlate of vaccine-induced protection has yet to be identified for TB, both interferon (IFN)- and interleukin-17A (IL-17) production by CD4 + T cells are targeted in vaccine-induced immunity to Mtb infection. 3, 4 In addition, since mice lacking major histocompatibility complex (MHC)-I processing machinery or CD8 + T cells are more susceptible to TB disease, 5, 6 CD8 + T cells have been implicated as having a role in control of Mtb infection. The novel multivalent DNA TB vaccine, RSQ-15, is designed using the pVax1 vector. The vector was used to express 15 synthetic consensus antigens of the Mtb ESX gene family (esxO, esxR, esxF, esxB, esxC, esxU, esxH, esxA, esxT, esxD, esxQ, esxE, esxV, esxS, and esxW). The antigens were selected based on diversity and cross-reactivity, 7 with the unique goal of inducing an immune response across a broad range of Mtb antigens, namely all 23 members of the ESX secretion system. The ESX secretion system is a family of Mtb proteins associated with mycobacterial virulence 8 and contains several epitopes able to induce T cell responses in both humans and in animal models. 9 , 10 RSQ-15 is delivered intramuscularly (i.m.) followed by electroporation at the site of immunization in order to improve the immunogenicity of the DNA vector. 7, 11 Finally, to further expand the antigen repertoire of RSQ-15, we also included a plasmid expressing Ag85B (pAg85B), a mycolyl transferase expressed in a system unrelated to the ESX secretion system. 16 Mice were immunized as described previously, with the inclusion of although not to levels induced by intranasal (i.n.) administration. 17 In a similar study comparing BCG administered s.c. followed by either i.m. or i.n.-administered AdAg85A, IFN- production in the bronchoalveolar lavage fluid was significantly lower in mice receiving a parenteral boost compared to those receiving a mucosal boost. 18 Thus, the ability of parenterally-delivered RSQ-15 to induce potent IFN- production in the lungs is, to our knowledge, unique.
The pVax1 expression system along with electroporation has primarily been used for immunization against viruses, and as such has been shown to be a potent inducer of CD8 + T cells. 12, 14, 19 RSQ-15 is also a potent inducer of CD8 + T cells, although CD4 + T cells are also induced, albeit to a lesser extent. 7 Although we did not assess which T cell subset was responsible for cytokine production in the lungs, it is likely, based on T cell subsets induced in the periphery, that the major cytokine-producing subset is CD8 + T cells. RSQ-15 is therefore unique in that it is the first multi-antigen TB vaccine to induce predominantly CD8 adjuvanted with mtrIL-33, 11 suggesting that some feature of the Ag85B protein makes it a good candidate for being adjuvanted by mtrIL-33, perhaps due to the signalling mechanism of the protein through toll-like receptors or other pattern recognition receptors. 23, 24 ESAT-6, a member of the ESX secretion system, and one of the proteins expressed in RSQ-15, has been shown to inhibit cytokine production by T cells; 25 it is therefore possible that the presence of ESAT-6 or other ESX proteins interferes with mtrIL-33 signalling through its receptor, ST2, and that the presence of Ag85B is required to overcome this.
Although RSQ-15 induces potent IFN- production, we detected no IL-17 induction.
Given the importance of IL-17 in vaccine-induced protection against TB disease, 4, 15 we aimed to induce the cytokine using a plasmid expressing IL-23, a cytokine essential to the proliferation of Th17 cells. Previous studies using DNA immunization and electroporation for the treatment of tumors used a plasmid expressing IL-23 to enhance Th17 responses.
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Here, however, our attempt to induce IL-17 following RSQ-15 immunization using a plasmid expressing IL-23 failed. The reason for this is unclear, and could be due to a number of factors. It is possible that the antigens used are not conducive for the induction of Th17 cells, however this is unlikely, as we have previously shown that both ESAT-6 and Ag85B are able to induce IL-17 production. 27 Alternatively, it could be that the dose and length of electroporation either does not target Th17-inducing antigen-presenting cells, or induces non-responsiveness of antigen-presenting cell subsets responsible for Th17 induction. The synthetic DNA vaccine studied here delivered with electroporation represents a promising avenue to pursue for development of a novel multivalent TB vaccine, not least due to the fact that the approach has already been shown to be safe and very immune potent in humans. 12, 19 Furthermore, given that pVax1 is a non-replicating vector, RSQ-15 could be safely administered to immunocompromised individuals. This is in contrast to BCG, which is contraindicated in infants exposed to HIV due to the risk of developing 'BCG-osis'. This, along with the novel approach for inducing immunogenicity against a broad range of immunodominant and non-immunodominant antigens, suggests RSQ-15 is a promising vaccine candidate for future TB vaccines.
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